News Release

Examining risk of vision impairment, loss associated with use of erectile dysfunction drugs

JAMA Ophthalmology

Peer-Reviewed Publication

JAMA Network

What The Study Did: This cohort study examines the risk for ocular adverse events (serous retinal detachment, retinal vascular occlusion and ischemic optic neuropathy) among men using phosphodiesterase type 5 inhibitors (erectile dysfunction drugs that are one of the most prescribed classes of medications in the United States).

Authors: Mahyar Etminan, Pharm.D., M.Sc., of the University of British Columbia in Vancouver, Canada, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.